51 recruiting. 51 Phase 3, 6 Phase 2.
By phase and status
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Trials (filtered) newest first · largest first
All 51 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) Phase 3 Recruiting 750 2026-09-24 2026-10-21 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency Phase 3 Recruiting 63 2026-09-15 2026-10-14 A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma Phase 3 Recruiting 1000 2026-09-09 2026-11-03 Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma Phase 3 Recruiting 500 2026-09-01 2026-08-17 D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma Phase 3 Recruiting 720 2026-08-31 2026-10-09 Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) Phase 3 Recruiting 1226 2026-07-01 2026-07-15 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AZD0120, Daratumumab, Dexamethasone - Newly Diagnosed Multiple Myeloma Phase 3 Recruiting 750 2026-06-26 2026-08-14 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma Phase 3 Recruiting 380 2026-06-23 2026-10-13 A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone - Myeloma Multiple Phase 3 Recruiting 390 2026-06-15 2026-08-03 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma Phase 3 Recruiting 255 2026-06-11 2026-09-17 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322, Teclistamab - Multiple Myeloma Phase 3 Recruiting 700 2026-05-31 2026-09-25 A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Linvoseltamab, Daratumumab - High Risk Smoldering Multiple Myeloma (HR-SMM) Phase 3 Recruiting 270 2026-05-21 2026-11-04 A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Phase 3 Recruiting 49 2026-05-11 2026-10-01 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm Phase 2 / Phase 3 Recruiting 30 2026-04-01 2026-08-17 A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma GR1803 injection, Daratumumab, Pomalidomide - Multiple Myeloma Phase 3 Recruiting 358 2026-03-09 2026-03-25 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma Phase 3 Recruiting 508 2026-02-23 2026-09-29 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322, Teclistamab - Multiple Myeloma Phase 3 Recruiting 400 2026-02-04 2026-11-03 A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) - Relapsed or Refractory Multiple Myeloma (RRMM) Phase 3 Recruiting 261 2026-01-25 2026-05-12 A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma IGI, 10% - Multiple Myeloma, Secondary Immunodeficiency Phase 3 Recruiting 183 2026-01-14 2026-10-13 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Etentamig, Lenalidomide, Daratumumab - Multiple Myeloma Phase 2 / Phase 3 Recruiting 680 2026-01-08 2026-10-19
Showing 20 of 51. Sign in to see all of them.
Narrower conditions Recurrence (6) · Hematologic Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Neoplasms, Plasma Cell (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Erdheim-Chester Disease (2) · Glioma (2) · Laryngeal Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Ovarian Neoplasms (2)
Broader conditions Blood Protein Disorders (51) · Cardiovascular Diseases (51) · Hematologic Diseases (51) · Hemic and Lymphatic Diseases (51) · Hemorrhagic Disorders (51) · Hemostatic Disorders (51) · Immune System Diseases (51) · Immunoproliferative Disorders (51) · Paraproteinemias (51) · Vascular Diseases (51) · Lymphoproliferative Disorders (50) · Neoplasms (49) · Neoplasms by Histologic Type (49) · Neoplasms, Plasma Cell (48) · Pathological Conditions, Signs and Symptoms (13)
Interventions Dexamethasone (34) · daratumumab (23) · Lenalidomide (17) · Bortezomib (15) · pomalidomide (15) · carfilzomib (6) · Calcium Dobesilate (5) · Cyclophosphamide (4) · elotuzumab (3) · fludarabine (3) · isatuximab (3) · selinexor (3) · Fumigant 93 (2) · Hizentra (2) · Injections (2)
Sponsors Janssen Research & Development, LLC (4) · AstraZeneca (3) · Pfizer (3) · Cancer Research UK (2) · European Myeloma Network B.V. (2) · Regeneron Pharmaceuticals (2) · The Affiliated People's Hospital of Ningbo University (2) · University of Leeds (2) · AbbVie (1) · Assistance Publique - Hôpitaux de Paris (1) · Augusta University (1) · Biocad (1) · CSL Behring (1) · Canadian Cancer Trials Group (1) · Celgene (1)
Countries United States (27) · China (23) · United Kingdom (22) · France (21) · Italy (19) · Spain (19) · Australia (18) · Canada (18) · Germany (18) · Poland (17) · Brazil (16) · Japan (16) · South Korea (16) · Czechia (14) · Greece (14)
Top investigators Arina Zinkina (1) · Charlotte Pawlyn (1) · Claudia Stege (1) · Clifton C. Mo, MD (1) · Daniel S. Childs, MD (1) · David Greenberg, MD (1)
Results publications PMID 39167092 , PMID 40558019 , PMID 41239440 , PMID 41429779
NIH funding 2023 (5) , 2025 (4) , 2016 (1) , U10CA180820 (1) , U10CA180888 (1)